Open AccessCompany Profile: Altor BioScience Corporation
Author(s) -
Hing C. Wong
Publication year - 2010
Publication title -
biomarkers in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 44
eISSN - 1752-0371
pISSN - 1752-0363
DOI - 10.2217/bmm.10.69
Subject(s) - medicine , monoclonal antibody , chimeric antigen receptor , immunotherapy , immunology , antibody , immune system
Altor BioScience Corporation is a privately held, development-stage company engaged in the discovery and development of targeted immunotherapeutic agents for the treatment of cancer, viral infection and inflammatory diseases. Altor currently has three targeted immunotherapeutic products in clinical development. Two of these products are monoclonal antibodies, but the third is a novel molecule that utilizes targeting based on Altor’s single-chain T-cell receptor (scTCR) STAR™ technology. In addition to therapeutic applications, this scTCR STAR technology has enabled Altor to develop novel reagents for research use to identify disease-associated antigens derived from intracellular proteins as biomarkers.